难治性中重度溃疡性结肠炎的生物制剂治疗研究进展  

Research advances of biological therapy for refractory moderate to severe ulcerative colitis

作　　者：汪海潮 叶晨(综述) 王晓蕾(审校)[1] WANG Hai-chao;YE Chen;WANG Xiao-lei(Dept.of Gastroenterology,Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China;Medical College of Soochow University,Suzhou 215000,Jiangsu Province,China)

机构地区：[1]同济大学附属第十人民医院消化内科,上海200072 [2]苏州大学医学部,江苏苏州215000

出　　处：《同济大学学报（医学版）》2020年第1期136-140,共5页Journal of Tongji University(Medical Science)

基　　金：国家自然科学基金面上项目(81670476)

摘　　要：溃疡性结肠炎(ulcerative colitis, UC)是炎症性肠病的一种表现形式,可导致严重不良后果。临床常规用药包括氨基水杨酸制剂、糖皮质激素、免疫抑制剂,但仍有部分难治性中重度UC患者对常规治疗无效,需要转换至生物制剂治疗。目前用于临床治疗UC有效的生物制剂有3类(抗肿瘤坏死因子-α抗体、抗整合素α4β7制剂、肌酸激酶抑制剂)。本文旨在从药物作用机制、疗效及不良反应等方面总结各生物制剂治疗难治性中重度UC的特点,为临床用药提供参考。Ulcerative colitis(UC) is a kind of inflammatory bowel disease(IBD), which can result in significant morbidity. Routine clinical drugs(including aminosalicylates, corticosteroids and immunosuppressive agents) are effective in most cases, but some patients with refractory moderate to severe UC are still ineffective with conventional treatment and need to be transferred to biological agents. At present, the anti-TNF-α antibodies, anti-integrin α4β7 and Janus kinase(JAK) inhibitor are effective biological agents for the treatment of refractory moderate to severe UC. This article reviews the characteristics of related biological agents to provide reference for treatment of refractory UC.

关 键 词：溃疡性结肠炎 生物制剂 抗TNF-α类药物 抗整合素制剂 JAK抑制剂 

分 类 号：R574.62[医药卫生—消化系统]